U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07036185) titled 'A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors' on June 10.
Brief Summary: This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors.
Study Start Date: June 24
Study Type: INTERVENTIONAL
Condition:
Gastric/Gastroesophageal Junction Cancer
Breast Cancer
Colorectal Cancer
Non-small Cell Lung Cancer (NSCLC)
Bile Duct Cancer
Head and Neck Squamous Cell Carcinoma
Intervention:
DRUG: KJ015 Injection (Subcutaneous Injection)
KJ015 is administered via subcutaneous i...